Approvals in 2016: questioning the clinical benefit of anticancer therapies

Nat Rev Clin Oncol. 2017 Feb 20;14(3):135-136. doi: 10.1038/nrclinonc.2017.18.

Authors

Christopher M Booth¹, Joseph C Del Paggio²

Affiliations

¹ Departments of Oncology and Public Health Sciences, Queen's University, University Avenue, Kingston, Ontario K7L 3N6, Canada.
² Department of Medicine, Division of Medical Oncology, University of Toronto, King's College Circus, Toronto, Ontario M5S, Canada.

PMID: 28218259
DOI: 10.1038/nrclinonc.2017.18

No abstract available

Publication types

Research Support, Non-U.S. Gov't

MeSH terms

Antineoplastic Agents / economics
Antineoplastic Agents / therapeutic use*
Cost-Benefit Analysis
Drug Approval / statistics & numerical data*
Drug Costs / statistics & numerical data
Humans
Neoplasms / drug therapy*
Treatment Outcome

Substances

Antineoplastic Agents